Skip to content

Study · Observational study · n = 57 · 2026

8 results

Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency.

Oi-Yo Y, Urai S, Yamamoto M, Tomofuji S, Ohmachi Y, Sasaki Y, Bando H, Takahashi M, Iguchi G, Harada R, Sakai Y, Fukuoka H

The Journal of clinical endocrinology and metabolism1 Aug 2026

PMID41955533 (opens in a new tab)DOI10.1210/clinem/dgag153 (opens in a new tab)PepBankPUB-41955533
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with GH deficiency, total lean mass change did not differ between somapacitan and daily GH (difference -0.2 kg).

    In plain wordsIn adults with GH deficiency, lean mass change did not differ between somapacitan and daily GH.

    Peptide
    Somapacitan
    Outcome
    No significant changeTotal lean mass change at week 52
    Study

    n = 57

    Comparator
    Continued daily GH
    Analysis
    Primary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −0.2 kg
    total lean mass
    95% CI
    −1.5 to 1.1 kg
    mean difference

    Source sentences

    Summary
    The primary endpoint showed no between-group difference (mean difference -0.2 kg; 95% CI -1.5 to 1.1).
    2 context sentences
    Summary · context
    The prespecified primary endpoint was the dual-energy X-ray absorptiometry-derived change in total lean mass from baseline to week 52.
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  2. 02HumanObservational studyEfficacy outcome

    In adults with GH deficiency, switching to somapacitan was associated with increased adiposity indices.

    In plain wordsIn adults with GH deficiency, switching to somapacitan was linked to increased measures of body fat.

    Peptide
    Somapacitan
    Outcome
    IncreaseAdiposity indices
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somapacitan was associated with increased adiposity indices, yet it improved high-density lipoprotein-cholesterol.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  3. 03HumanObservational studyEfficacy outcome

    In adults with GH deficiency, switching to somapacitan was associated with improved HDL cholesterol; the abstract did not give values.

    In plain wordsIn adults with GH deficiency, switching to somapacitan was linked to improved HDL cholesterol.

    Peptide
    Somapacitan
    Outcome
    Direction not reportedHDL cholesterol
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somapacitan was associated with increased adiposity indices, yet it improved high-density lipoprotein-cholesterol.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  4. 04HumanObservational studyEfficacy outcome

    In adults with GH deficiency, switching to somapacitan was associated with improved handgrip strength in exploratory analyses.

    In plain wordsIn adults with GH deficiency, switching to somapacitan was linked to improved handgrip strength.

    Peptide
    Somapacitan
    Outcome
    Direction not reportedHandgrip strength
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exploratory analyses revealed improvements in handgrip strength and Timed Up and Go Test.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  5. 05HumanObservational studyEfficacy outcome

    In adults with GH deficiency, switching to somapacitan was associated with improved Timed Up and Go Test performance in exploratory analyses.

    In plain wordsIn adults with GH deficiency, switching to somapacitan was linked to improved Timed Up and Go Test performance.

    Peptide
    Somapacitan
    Outcome
    Direction not reportedTimed Up and Go Test
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exploratory analyses revealed improvements in handgrip strength and Timed Up and Go Test.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  6. 06HumanObservational studyEfficacy outcome

    In adults with GH deficiency, IGF-1 score distributions were similar with somapacitan and daily GH at week 52.

    In plain wordsIn adults with GH deficiency, IGF-1 score distributions were similar with somapacitan and daily GH at week 52.

    Peptide
    Somapacitan
    Outcome
    No significant changeIGF-1 score distributions at week 52
    Study

    n = 57

    Comparator
    Continued daily GH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Baseline and week 52 insulin-like growth factor 1 standard deviation scores distributions were similar between the groups; yet the increase was greater with daily GH than with somapacitan.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  7. 07HumanObservational studyEfficacy outcome

    In adults with GH deficiency, switching to somapacitan was associated with a smaller IGF-1 score increase than continued daily GH.

    In plain wordsIn adults with GH deficiency, switching to somapacitan was linked to a smaller IGF-1 score increase than daily GH.

    Peptide
    Somapacitan
    Outcome
    DecreaseIGF-1 score increase
    Study

    n = 57

    Comparator
    Continued daily GH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Baseline and week 52 insulin-like growth factor 1 standard deviation scores distributions were similar between the groups; yet the increase was greater with daily GH than with somapacitan.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.
  8. 08HumanObservational studySafety outcome

    In adults with GH deficiency, no new safety concerns were observed after switching to somapacitan.

    In plain wordsIn adults with GH deficiency, the study reported no new safety concerns after switching to somapacitan.

    Peptide
    Somapacitan
    Outcome
    Not applicableNew safety concerns
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No new safety concerns were observed.
    1 context sentence
    Summary · context
    Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.